BRPI0416227A - micropartìculas compreendendo análogos de somatostatina - Google Patents
micropartìculas compreendendo análogos de somatostatinaInfo
- Publication number
- BRPI0416227A BRPI0416227A BRPI0416227-7A BRPI0416227A BRPI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A
- Authority
- BR
- Brazil
- Prior art keywords
- microparticles
- somatostatin analogs
- somatostatin
- biocompatible
- understanding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
Abstract
"MICROPARTìCULAS COMPREENDENDO ANáLOGOS DE SOMATOSTATINA". A presente invenção refere-se a micropartículas compreendendo um análogo de somatostatina incrustadas em uma matriz polimérica biocompatível e farmacologicamente aceitável para uma liberação de longa ação e composições farmacêuticas compreendendo essas micropartículas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0326602.0 | 2003-11-14 | ||
GB0326602A GB0326602D0 (en) | 2003-11-14 | 2003-11-14 | Organic compounds |
GB0406241.0 | 2004-03-19 | ||
GB0406241A GB0406241D0 (en) | 2004-03-19 | 2004-03-19 | Organic compounds |
PCT/EP2004/012870 WO2005046645A1 (en) | 2003-11-14 | 2004-11-12 | Microparticles comprising somatostatin analogues |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0416227A true BRPI0416227A (pt) | 2007-01-02 |
BRPI0416227B1 BRPI0416227B1 (pt) | 2019-06-18 |
BRPI0416227B8 BRPI0416227B8 (pt) | 2021-05-25 |
Family
ID=34593737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416227A BRPI0416227B8 (pt) | 2003-11-14 | 2004-11-12 | micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit |
Country Status (31)
Country | Link |
---|---|
US (3) | US7759308B2 (pt) |
EP (1) | EP1686964B9 (pt) |
JP (1) | JP4682145B2 (pt) |
KR (1) | KR101233892B1 (pt) |
AR (1) | AR047310A1 (pt) |
AT (1) | ATE455537T1 (pt) |
AU (1) | AU2004289055C1 (pt) |
BR (1) | BRPI0416227B8 (pt) |
CA (1) | CA2541944C (pt) |
CY (2) | CY1110293T1 (pt) |
DE (1) | DE602004025271D1 (pt) |
DK (1) | DK1686964T3 (pt) |
EC (1) | ECSP066565A (pt) |
ES (1) | ES2339026T3 (pt) |
HK (1) | HK1093682A1 (pt) |
HR (1) | HRP20100190T1 (pt) |
IL (1) | IL175286A (pt) |
IS (1) | IS8480A (pt) |
LU (1) | LU92701I2 (pt) |
MA (1) | MA28155A1 (pt) |
MX (1) | MXPA06005357A (pt) |
MY (1) | MY158342A (pt) |
NO (2) | NO337172B1 (pt) |
NZ (1) | NZ546788A (pt) |
PE (1) | PE20050581A1 (pt) |
PL (1) | PL1686964T3 (pt) |
PT (1) | PT1686964E (pt) |
RU (1) | RU2404749C2 (pt) |
SI (1) | SI1686964T1 (pt) |
TW (1) | TWI295178B (pt) |
WO (1) | WO2005046645A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
ES2755032T3 (es) * | 2005-12-22 | 2020-04-21 | Novartis Ag | Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido |
KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
AR066677A1 (es) * | 2007-05-24 | 2009-09-02 | Novartis Ag | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. |
RU2541104C2 (ru) * | 2008-01-30 | 2015-02-10 | Новартис Аг | Препаративная форма с замедленным высвобождением, содержащая октреотид и три линейных полимера поли(лактид-со-гликолида) |
JP5562324B2 (ja) | 2008-04-03 | 2014-07-30 | ザイモジェネティクス, インコーポレイテッド | 止血マイクロスフェア |
JP5721624B2 (ja) | 2008-07-08 | 2015-05-20 | ノバルティス アーゲー | 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用 |
AR074603A1 (es) * | 2008-12-15 | 2011-01-26 | Novartis Ag | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit |
US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
US8569421B2 (en) | 2009-04-23 | 2013-10-29 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
WO2013131879A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
CN105189643B (zh) | 2012-08-30 | 2019-01-15 | 派诺聚合物技术公司 | 用于水力压裂液的双重机制增稠剂 |
EP2951220B1 (en) | 2013-02-04 | 2020-11-25 | Pilot Polymer Technologies, Inc. | Salt-tolerant star macromolecules |
EP2986278A1 (en) | 2013-03-11 | 2016-02-24 | DURECT Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及/或治療多囊腎病之藥物 |
JP6689210B2 (ja) | 2014-07-03 | 2020-04-28 | パイロット ポリマー テクノロジーズ, インク. | 界面活性剤相溶性星形高分子 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU221294B1 (en) | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
AU5678398A (en) | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
DK1098660T3 (da) * | 1998-07-23 | 2003-02-17 | Sod Conseils Rech Applic | Indkapsling af vandopløselige peptider |
WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
EP1240896A3 (en) | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
DE60006250T2 (de) | 1999-08-18 | 2004-07-29 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Formulierung zur verzögerten freisetzung von peptiden |
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
AU2003221497A1 (en) * | 2002-03-13 | 2003-09-22 | Novartis Ag | Pharmaceutical microparticles |
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
-
2004
- 2004-11-09 MY MYPI20044662A patent/MY158342A/en unknown
- 2004-11-11 AR ARP040104157A patent/AR047310A1/es not_active Application Discontinuation
- 2004-11-12 DK DK04797866.3T patent/DK1686964T3/da active
- 2004-11-12 DE DE602004025271T patent/DE602004025271D1/de active Active
- 2004-11-12 AU AU2004289055A patent/AU2004289055C1/en active Active
- 2004-11-12 PE PE2004001111A patent/PE20050581A1/es active IP Right Grant
- 2004-11-12 ES ES04797866T patent/ES2339026T3/es active Active
- 2004-11-12 PT PT04797866T patent/PT1686964E/pt unknown
- 2004-11-12 BR BRPI0416227A patent/BRPI0416227B8/pt active IP Right Grant
- 2004-11-12 WO PCT/EP2004/012870 patent/WO2005046645A1/en active Application Filing
- 2004-11-12 MX MXPA06005357A patent/MXPA06005357A/es active IP Right Grant
- 2004-11-12 NZ NZ546788A patent/NZ546788A/en unknown
- 2004-11-12 EP EP04797866A patent/EP1686964B9/en active Active
- 2004-11-12 TW TW093134728A patent/TWI295178B/zh active
- 2004-11-12 KR KR1020067009270A patent/KR101233892B1/ko active IP Right Grant
- 2004-11-12 RU RU2006120484/15A patent/RU2404749C2/ru active
- 2004-11-12 PL PL04797866T patent/PL1686964T3/pl unknown
- 2004-11-12 CA CA2541944A patent/CA2541944C/en active Active
- 2004-11-12 US US10/579,186 patent/US7759308B2/en active Active
- 2004-11-12 JP JP2006538808A patent/JP4682145B2/ja active Active
- 2004-11-12 SI SI200431378T patent/SI1686964T1/sl unknown
- 2004-11-12 AT AT04797866T patent/ATE455537T1/de active
-
2006
- 2006-04-27 IL IL175286A patent/IL175286A/en active IP Right Grant
- 2006-05-11 MA MA29019A patent/MA28155A1/fr unknown
- 2006-05-12 EC EC2006006565A patent/ECSP066565A/es unknown
- 2006-05-23 IS IS8480A patent/IS8480A/is unknown
- 2006-06-14 NO NO20062777A patent/NO337172B1/no active Protection Beyond IP Right Term
-
2007
- 2007-01-04 HK HK07100155.4A patent/HK1093682A1/xx unknown
-
2010
- 2010-03-09 CY CY20101100222T patent/CY1110293T1/el unknown
- 2010-04-01 HR HR20100190T patent/HRP20100190T1/hr unknown
- 2010-06-08 US US12/796,132 patent/US8188037B2/en active Active
-
2012
- 2012-04-26 US US13/456,681 patent/US20120214749A1/en not_active Abandoned
-
2015
- 2015-03-26 CY CY2015011C patent/CY2015011I2/el unknown
- 2015-04-29 LU LU92701C patent/LU92701I2/xx unknown
-
2016
- 2016-02-02 NO NO2016003C patent/NO2016003I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0416227A (pt) | micropartìculas compreendendo análogos de somatostatina | |
NO20062111L (no) | 2-(3,4-dimetylfenyl)-4-{[2-hydroksy-3'(1H-tetrazol-5-yl)]-hydrazon}-5-metyl-2,4-dihydropyrozol-3-on kolin. | |
ZA200610511B (en) | Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine | |
HK1076742A1 (en) | Orodispersible pharmaceutical composition comprising agomelatine | |
EP1560569A4 (en) | GASTRORETENTIVE LEVODOPA DELIVERY FORM | |
IL232408A0 (en) | 3303 * a-hla – reduced 1wt peptide and pharmaceutical compound containing it | |
IL215334A0 (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
IL165029A0 (en) | Modified release pharmaceutical formulation | |
GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
BR0313428A (pt) | Composições farmacêuticas de drogas semi-ordenados e polìmeros | |
DE60305728D1 (de) | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG | |
ECSP056237A (es) | Composición farmacéutica que comprende análogos de somatostatina cíclicos | |
BRPI0408848A (pt) | formulações orais de cladribine | |
BRPI0516922A (pt) | composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica | |
ATE448780T1 (de) | Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung | |
EP1478353A4 (en) | PHARMACEUTICAL COMPOSITION WITH DELAYED RELEASE | |
DK1467750T3 (da) | Orodispergerbar farmaceutisk sammensætning omfattende perindopril | |
TNSN06136A1 (en) | Microparticles comprising somatostatin analogues | |
TNSN05310A1 (en) | Pharmaceutical composition comprising cyclic somatostatin analogues | |
MX2008006476A (es) | Composiciones de lipopeptidos. | |
RS50975B (sr) | Kompozicije koje obuhvataju molekularno dispergovani drospirenon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/16 , A61K 38/31 Ipc: A61K 38/31 (2006.01), A61K 9/16 (2006.01), A61P 5/ |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B25A | Requested transfer of rights approved |
Owner name: RECORDATI AG (CH) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |